Lenalidomide-mediated erythroid improvement in non-del(5q) myelodysplastic syndromes is associated with bone marrow immuno-remodeling

[1]  P. Laurent-Puig,et al.  Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression , 2016, Genome Biology.

[2]  G. Mufti,et al.  Randomized Phase III Study of Lenalidomide Versus Placebo in RBC Transfusion-Dependent Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes and Ineligible for or Refractory to Erythropoiesis-Stimulating Agents. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  J. Tavernier,et al.  Lenalidomide Stabilizes the Erythropoietin Receptor by Inhibiting the E3 Ubiquitin Ligase RNF41. , 2016, Cancer research.

[4]  A. Stamatoullas,et al.  Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion , 2016, Leukemia.

[5]  A. Stamatoullas,et al.  Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. , 2016, Blood.

[6]  S. Carr,et al.  Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS , 2015, Nature.

[7]  J. Lancet,et al.  Combined treatment with lenalidomide and epoetin alfa in lower-risk patients with myelodysplastic syndrome. , 2012, Blood.

[8]  Dung-Tsa Chen,et al.  Reversal of T-cell Tolerance in Myelodysplastic Syndrome through Lenalidomide Immune Modulation , 2011, Leukemia.

[9]  M. Cazzola,et al.  A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. , 2011, Blood.

[10]  G. Ossenkoppele,et al.  Role of immune responses in the pathogenesis of low‐risk MDS and high‐risk MDS: implications for immunotherapy , 2011, British journal of haematology.

[11]  J. Trapani,et al.  The immunostimulatory effect of lenalidomide on NK-cell function is profoundly inhibited by concurrent dexamethasone therapy. , 2011, Blood.

[12]  Pablo Tamayo,et al.  An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome , 2008, PLoS medicine.

[13]  M. Gordon.  Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion , 2008 .

[14]  J. Bourhis,et al.  Cytolytic function and survival of natural killer cells are severely altered in myelodysplastic syndromes , 2006, Leukemia.

[15]  P. Vyas,et al.  Evidence for reduced B-cell progenitors in early (low-risk) myelodysplastic syndrome. , 2005, Blood.

[16]  N. Young,et al.  Preferential suppression of trisomy 8 compared with normal hematopoietic cell growth by autologous lymphocytes in patients with trisomy 8 myelodysplastic syndrome. , 2003, Blood.

[17]  P. Linton,et al.  Age-related changes in lymphocyte development and function , 2004, Nature Immunology.